---
layout: default
title: Fluorometholone
parent: 僅模型預測 (L5)
nav_order: 270
evidence_level: L5
indication_count: 10
---

# Fluorometholone
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Fluorometholone: From Ocular Inflammation to Postinfectious Vasculitis

## One-Sentence Summary

Detailed original-indication data for fluorometholone is not present in this evidence pack, but it is a well-known topical ophthalmic corticosteroid used for steroid-responsive ocular inflammation. The TxGNN model's top-ranked prediction is **Postinfectious Vasculitis**, but this direction is currently supported by **0 clinical trials** and **0 publications**, and the model's own rationale flags the mechanistic link as weak.

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | Not available in this dataset (known clinically as a topical corticosteroid for steroid-responsive ocular inflammation) |
| Predicted New Indication | Postinfectious Vasculitis |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| Saudi Arabia Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for fluorometholone in this dataset. Based on known information, fluorometholone belongs to the topical ophthalmic corticosteroid class, and its efficacy in steroid-responsive ocular inflammatory conditions has been clinically established.

However, the repurposing rationale supplied for this specific prediction explicitly cautions against the link: a locally-applied ophthalmic steroid lacks the pharmacokinetic basis to reach therapeutic systemic concentrations needed to treat a systemic postinfectious vasculitis. The mechanistic connection is assessed as weak, and — unlike several lower-ranked predictions in this same pack (e.g., "post-bacterial disorder," rank 2, which has real Phase 2 trial support) — no clinical trial or literature evidence currently exists to counterbalance this concern.

## Clinical Trial Evidence

Currently no related clinical trials registered.

## Literature Evidence

Currently no related literature available.

## Saudi Arabia Market Information

Fluorometholone is not currently marketed in Saudi Arabia and has no product authorizations on file (0 licenses).

## Safety Considerations

Please refer to the package insert for safety information. (Key warnings, contraindications, and drug interaction data are not available for this drug in the current dataset — TFDA package insert retrieval is flagged as a blocking data gap.)

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication has no supporting clinical trials or literature, and the model's own mechanistic rationale identifies a pharmacokinetic barrier (topical ocular route vs. systemic disease) rather than a plausible pathway — this is a pure model-score signal (L5) with no corroborating evidence.

**To proceed, the following is needed:**
- TFDA/regulatory package insert (warnings, contraindications) — currently a blocking gap
- Mechanism of action (MOA) detail from DrugBank
- Preclinical or case-level evidence specifically linking fluorometholone (or systemic corticosteroids generally) to postinfectious vasculitis
- Consider prioritizing rank 2 ("post-bacterial disorder," L3, active Phase 2 trial NCT07308938) as a better-evidenced alternative candidate for this drug
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

